人乳头状瘤病毒DNA恒温扩增技术在宫颈癌筛查中的应用价值  

Application of isothermal HPV DNA amplification test in cervical cancer screening

作　　者：王林[1] 姜明月 秦宇 李莉[3] 吴泽妮 李婷媛 吴婷[1] 陈汶 Wang Lin;Jiang Mingyue;Qin Yu;Li Li;Wu Zeni;Li Tingyuan;Wu Ting;Chen Wen(State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China;Department of Cancer Epidemiology, National Cancer Center~Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;School of Public Health, Xifiang University, Urumqi 830011, China)

机构地区：[1]厦门大学分子疫苗学和分子诊断学国家重点实验室国家传染病诊断试剂与疫苗工程技术研究中心公共卫生学院,361102 [2]国家癌症中心中国医学科学院北京协和医学院肿瘤医院流行病学研究室,100021 [3]新疆医科大学公共卫生学院,乌鲁木齐830011

出　　处：《中华肿瘤杂志》2018年第4期313-318,共6页Chinese Journal of Oncology

摘　　要：目的评价人乳头状瘤病毒（HPV）DNA恒温扩增检测技术Isomega应用在高危型别HPVDNA检测及宫颈病变诊断中的可行性及有效性。方法招募2774名30-64岁来自内蒙古自治区健康妇女进行宫颈癌筛查。采用Isomega和cobas4800HPV检测技术进行HPVDNA检测，应用线性探针法（INNO-LiPA）对两种检测方法结果不一致的标本进行分型检测。以病理诊断为金标准，评价Isomega和cobas4800方法检出宫颈上皮内瘤变（CIN）2级及以上病变的有效性和准确性。结果Isomega与cobas4800检出HPVDNA的总一致率为94．84％（Kappa=0．82），检出HPVl6、HPVl8型和其他型别HR-HPV的一致率分别为99．68％（Kappa=0．95）、99．78％（Kappa=0．91）和94．34％（Kappa=0．76）。与INNO-LiPA校正结果比较，Isomega检出HPVl6、HPVl8和其他型别HR-HPV的一致率分别为99．71％（Kappa=0．95）、99．86％（Kappa=0．94）和95．76％（Kappa=0．87）；cobas4800的一致率分别为99．82％（Kappa=0．97）、99．86％（Kappa=0．94）和97．51％（Kappa=0．90）。Isomega检出CIN2＋（包括CIN2、CIN3和鳞癌）的敏感度和特异度分别为87．76％和82．94％，cobas4800分别为89．80％和85．06％。结论Isomega与cobas4800HPV检测方法的一致性较好，检测HPVl6和18型的准确性高，具有较高的敏感度和特异度．可用于临床检测和大规模人群的宫颈癌筛查。Objective To evaluate the feasibility and effectiveness of isothermal human papillomavirus （HPV） DNA amplification test as a primary screening test in the early detection of cervical cancer. Methods From June to August 2016, 2,774 women aged 30-64 years old from Inner Mongolia were recruited for cervical cancer screening. HPV DNA was detected by Isomega and cobas4800. INNO-LiPA HPV Genotyping Extra was served as a reference method for the cases whose results were inconsistent by using these two methods. Histological diagnosis was considered as a gold standard to estimate the effectiveness and accuracy of Isomega and cobas4800 for detecting CIN2 or greater. Results The concordance of Isomega and cobas4800 was 94.84% （Kappa = 0.82） for high risk HPV （HR-HPV） , 99.68% （Kappa=0.95） for HPV16, 99.78% （Kappa=0.91） for HPV18 and 94.34% （Kappa=0.76） for other HR-HPV types. The concordances of Isomega and the reference were 99.71% （ Kappa = 0.96） , 99.86% （Kappa = 0.94） and 96.76% （ Kappa = 0.87） for HPV16, 18 and other HR-HPV, respectively, while the concordances of cobas4800 and the reference were 99.82% （ Kappa = 0.97） , 99.86% （ Kappa =0.94） and 97.51% （Kappa= 0.90） , respectively. The sensitivity and specificity of Isomega for detecting CIN2＋ （including CIN2, CIN3 and squamous cell carcinoma） were 87.76% and 82.94%, respectively, while those of cobas4800 were 89.80% and 85.06%, respectively. Conclusions The concordances of Isomega and cobas4800 is confident. These two methods can accurately detect the HPV16 and 18 genotyping, and have good sensitivity and specificity for clinical diagnosis and population screening of cervical cancer.

关 键 词：人乳头状瘤病毒 宫颈肿瘤 筛查 

分 类 号：R737.33[医药卫生—肿瘤]